EAGLE PHARMACEUTICALS, INC.

Form S-8 March 20, 2017

As filed with the Securities and Exchange Commission on March 20, 2017

Registration No. 333-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

EAGLE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)

50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ
(Address of Principal Executive Offices)

20-8179278
(I.R.S. Employer Identification No.)

2014 Equity Incentive Plan

2014 Employee Stock Purchase Plan

	(Full titles of the plans)	
	Scott Tarriff	
	Scott Tarrin	
	Chief Executive Officer	
	Eagle Pharmaceuticals, Inc.	
	50 Tice Boulevard, Suite 315	
	Woodcliff Lake, NJ 07677	
	(201) 326-5300	
(Name, address, including zip code	, and telephone number, including	area code, of agent for service)
_		
	Copies to:	
		David E. Riggs
Marc Recht, Esq.		Chief Financial Officer
Cooley LLP 500 Boylston Street, 14th Floor		Eagle Pharmaceuticals, Inc. 50 Tice Boulevard, Suite 315
Boston, Massachusetts 02116		Woodcliff Lake, NJ 07677
(617) 937-2300		(201) 326-5300
Indicate by check mark whether the registrant is a large a	ccelerated filer, an accelerated file	r a non-accelerated filer or a smaller reporting
company. See the definitions of large accelerated filer, (Check one):		reporting company in Rule 12b-2 of the Exchange Act.

CALCULATION OF REGISTRATION FEE

o (Do not check if a smaller reporting

Accelerated filer

Smaller reporting company

Large Accelerated filer

Non-accelerated filer

o

company)

 \mathbf{X}

o

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form S-8 $\,$



EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,073,584 shares of Common Stock of Eagle Pharmaceuticals, Inc. (the Registrant) issuable pursuant to the Eagle Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended and restated (the 2014 EIP) and the Eagle Pharmaceuticals, Inc. 2014 Employee Stock Purchase Plan (the 2014 ESPP). These additional shares of Common Stock are securities of the same class as other securities for which an original registration statement on Form S-8 (File No. 333-194056) was filed with the Securities and Exchange Commission (the Commission) on February 21, 2014. These additional shares of Common Stock have become reserved for issuance as a result of the operation of the evergreen provisions in each of the 2014 EIP and the 2014 ESPP, which provide that the total number of shares subject to such plans will be increased each year pursuant to a specified formula.

PART II

INCORPORATION OF DOCUMENTS BY REFERENCE

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plans is effective.

The Registrant previously registered shares of its Common Stock for issuance under the 2014 EIP and the 2014 ESPP under Registration Statements on Form S-8 filed with the Commission on February 21, 2014 (File No. 333-194056), on September 2, 2015 (File No. 333-206729), and on September 16, 2016 (File No. 333-213683). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

2

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Woodcliff Lake, State of New Jersey, on March 20, 2017.

EAGLE PHARMACEUTICALS, INC.

By: /s/ Scott Tarriff

Scott Tarriff

Chief Executive Officer and Director

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Scott Tarriff and David E. Riggs, and each of them, as his true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him and in his name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/S/ SCOTT TARRIFF Scott Tarriff	Chief Executive Officer and Member of the Board of Directors (Principal Executive Officer)	March 20, 2017
/S/ DAVID E. RIGGS David E. Riggs	Chief Financial Officer (Principal Accounting and Financial Officer)	March 20, 2017
/S/ MICHAEL GRAVES Michael Graves	Chairman of the Board of Directors	March 20, 2017
/S/ STEVEN RATOFF Steven Ratoff	Member of the Board of Directors	March 20, 2017
/S/ SANDER FLAUM		

Sander Flaum	Member of the Board of Directors	March 20, 2017
/S/ ROBERT L. GLENNING Robert L. Glenning	Member of the Board of Directors	March 20, 2017
/S/ DOUGLAS L. BRAUNSTEIN Douglas L. Braunstein	Member of the Board of Directors	March 20, 2017
Richard A. Edlin	Member of the Board of Directors	March , 2017
	3	

EXHIBIT INDEX

Description Amended and Restated Certificate of Incorporation of the Registrant.
Amended and Restated Bylaws of the Registrant.
Form of Common Stock Certificate of the Registrant.
Opinion of Cooley LLP.
Consent of BDO USA, LLP, an Independent Registered Public Accounting Firm.
Consent of Cooley LLP. Reference is made to Exhibit 5.1.
Power of Attorney. Reference is made to the signature page hereto.
Eagle Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended and restated.
Eagle Pharmaceuticals, Inc. 2014 Employee Stock Purchase Plan.

Previously filed as Exhibit 3.2 to the Registrant s Registration Statement on Form S-1 (File No. 333-192984), filed with the Commission on January 28, 2014, and incorporated herein by reference.

Previously filed as Exhibit 3.4 to the Registrant s Registration Statement on Form S-1 (File No. 333-192984), filed with the Commission on January 28, 2014, and incorporated herein by reference.

Previously filed as Exhibit 4.1 to the Registrant s Registration Statement on Form S-1 (File No. 333-192984), filed with the Commission on January 28, 2014, and incorporated herein by reference.

Previously filed as Exhibit 10.1 to the Registrant s Current Report on Form 8-K (File No. 001-36306), filed with the Commission on August 10, 2015, and incorporated herein by reference.

Previously filed as Exhibit 10.4 to the Registrant s Registration Statement on Form S-1 (File No. 333-192984), filed with the Commission on January 22, 2014, and incorporated herein by reference.